Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
22.18 USD | -2.53% | -4.55% | +16.30% |
31/05 | Qiagen, Myriad Genetics Team Up to Develop Homologous Recombination Deficiency Test | MT |
31/05 | Qiagen, Myriad Genetics Partner to Create Easily Distributable Cancer Tumor Test | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+16.30% | 206Cr | |
-4.22% | 1.24TCr | |
-0.60% | 821.51Cr | |
+6.61% | 571.74Cr | |
-10.21% | 411.13Cr | |
-60.11% | 268.39Cr | |
+10.62% | 267.87Cr | |
-5.50% | 237.39Cr | |
-9.18% | 180.32Cr | |
-2.30% | 159.57Cr |
- Stock Market
- Equities
- MYGN Stock
- News Myriad Genetics, Inc.
- Piper Sandler Adjusts Price Target on Myriad Genetics to $28 From $23, Maintains Neutral Rating